HeartBeam, Inc. (BEAT)

HeartBeam's stock price has been impacted by several events in the past six months. In December 2025, the company received FDA 510(k) clearance for its 12-lead ECG synthesis software, leading to a surge in the stock price. In February 2026, Joseph Gunnar & Co. upgraded HeartBeam from Hold to Buy and raised its 12-month price target to $4. In March 2026, HeartBeam reported a net loss of $5.3 million for Q4 2025 and $21.0 million for the full year 2025. Several analysts initiated or maintained "Buy" ratings and price targets for HeartBeam, with an average one-year price target of $5.48 as of March 28, 2026. As of April 6, 2026, the share price was $1.20, representing a decline of 27.27% from $1.65 per share on April 7, 2025.

There is no explicit information indicating strong demand seasonality for HeartBeam, Inc.'s products and services. Demand is primarily driven by individual health events and ongoing cardiac monitoring needs rather than predictable seasonal patterns.

HeartBeam, Inc. is a medical technology company focused on transforming cardiac care through innovative ambulatory ECG solutions. The company operates within the Healthcare sector, specifically in the Healthcare Providers & Services and Medical Devices industries. Its core offering is a proprietary Vector Electrocardiography (VECG) technology platform that enables the creation of a cable-free device capable of collecting ECG signals in 3D and synthesizing them into a 12-lead ECG. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received FDA clearance in December 2025. The company also has a working prototype of an extended-wear 12-lead ECG patch.

The initial geographic market for the HeartBeam System is the United States. Primary customers are concierge physicians, cardiology practices, and cardiology departments of hospitals. Healthcare insurers are also considered important customers due to potential cost reductions to the healthcare system.

HeartBeam has garnered positive recognition for its innovative technology in the past year. HeartBeam was recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report. The company was highlighted among medical device innovators in an industry roundup by Modern Healthcare. HeartBeam announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG algorithms.

HeartBeam, Inc. has a diverse ownership structure. Institutional shareholders hold 11.11% of the stock, insiders hold 14.40%, and retail investors hold 74.50%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., UBS Group AG, and others. The largest individual shareholder is Mark E. Strome, owning 2.96 million shares, representing 7.20% of the company.